Holen Sie sich die Stockscreener-App
4.91
0.81%
-0.04
Schlusskurs vom Vortag:
$4.95
Offen:
$4.98
24-Stunden-Volumen:
276.67K
Relative Volume:
0.51
Marktkapitalisierung:
$66.13M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-27.71M
KGV:
-1.1522
EPS:
-4.2615
Netto-Cashflow:
$-19.77M
1W Leistung:
-8.74%
1M Leistung:
+0.41%
6M Leistung:
+6.05%
1J Leistung:
+10.84%
1-Tages-Spanne:
$4.70
$4.98
1-Wochen-Bereich:
$4.70
$5.65
52-Wochen-Spanne:
$3.16
$11.89
Cingulate Inc Stock (CING) Company Profile
Firmenname
Cingulate Inc
Sektor
Branche
Telefon
(913) 942-2300
Adresse
1901 W. 47TH PLACE, KANSAS CITY
Compare CING vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CING
Cingulate Inc
|
4.91 | 66.13M | 0 | -27.71M | -19.77M | -4.2615 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Cingulate Inc Stock (CING) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-01-10 | Eingeleitet | ROTH MKM | Buy |
| 2023-12-22 | Herabstufung | Laidlaw | Buy → Hold |
Cingulate Inc Aktie (CING) Neueste Nachrichten
CINGW Drops Nearly 10% as Warrants Continue Trading at Deeply Discounted LevelsWyckoff Upthrust - dars.gov.et
Cingulate (CING) Proxy Filing Summary - Quartr
CING Q1 2026 Earnings: Wider-than-Expected Loss Sends Shares LowerProfit Announcement - dars.gov.et
Enterprise value to revenue forward of Cingulate Inc. – NASDAQ:CING - TradingView
Cingulate, Inc. Warrant 2021-03.12.26 on Cingulate Financial Disclosures & SEC Filings - TradingView
Form 4 Cingulate Inc For: 2 July By Investing.com - Investing.com Canada
Cingulate (CING) EVP and CSO Raul Silva receives grant of 3,885 stock options - Stock Titan
Cingulate (NASDAQ: CING) Added to Russell 3000E® Index, Boosting Visibility and Growth in ADHD Market - Minichart
Cingulate added to Russell 3000E Index - Investing.com
Cingulate added to Russell 3000E Index By Investing.com - Investing.com Nigeria
Cingulate Inc. joins Russell 3000E® Index, boos... - Pluang
Index addition puts Cingulate (NASDAQ: CING) into the Russell 3000E - Stock Titan
Cingulate Inc. (NASDAQ: CING) Added to Russell 3000E® - GlobeNewswire
Why Is CING Stock Jumping Over 4% In Overnight Trading? - Stocktwits
Cingulate Inc. (CING) Surges 8.78% as Momentum Builds Near Key Resistance LevelPrice Momentum Stocks - dars.gov.et
CING News | CINGULATE INC (NASDAQ:CING) - ChartMill
Cingulate Inc.(NasdaqCM: CING) added to Russell Microcap Growth Benchmark Index - marketscreener.com
Cingulate Inc.(NasdaqCM: CING) added to Russell 3000E Growth Benchmark - marketscreener.com
Cingulate Inc.(NasdaqCM: CING) added to Russell Microcap Index - marketscreener.com
Cingulate Inc.(NasdaqCM: CING) added to Russell 3000E Index - marketscreener.com
Cingulate, Inc. Actuals & Estimates (NASDAQ:CING) - TradingView
CING Forecast — Price Target — Prediction for 2027 - TradingView
Cingulate Inc (CINGW) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
CING Stock Price, Quote & Chart - ChartMill
CINGW Warrants Decline Marginally, Remain in Narrow Trading Band at Penny LevelsIV Crush Alert - dars.gov.et
CING Q1 2026 Earnings: EPS Misses Estimates as Clinical-Stage Biotech Reports Wider-than-Expected Loss - dars.gov.et
Cingulate Inc (CINGW) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Cingulate Inc (CINGW) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Cingulate Inc (CINGW) Institutional Confidence - TradingKey
Cingulate Inc (CINGW) Valuation: PE, PB & Fair Value Analysis - TradingKey
Cingulate Inc (CINGW) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Cingulate Inc (CING) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Cingulate Inc (CING) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Cingulate Inc (CING) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Cingulate Inc (CING) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Cingulate Inc (CING) Valuation: PE, PB & Fair Value Analysis - TradingKey
Cingulate Inc (CING) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Cingulate Inc (CING) Institutional Confidence - TradingKey
Cingulate Inc (CING) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Cingulate Inc (CING) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Cingulate Inc (CINGW) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Cingulate Inc (CINGW) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Cingulate Inc (CINGW) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Cingulate Issued First U.S. Patent for Lead ADHD Asset CTx-1301 - markets.businessinsider.com
Cingulate Secures First U.S. Patent for CTx-1301 ADHD Drug, Extending Exclusivity to 2042 - Minichart
Cingulate issued U.S. patent for CTx-1301, exclusivity extended into Dec 2042 - TradingView
US patent extends Cingulate (NASDAQ: CING) CTx-1301 ADHD exclusivity - Stock Titan
Cingulate Inc. Warrants (CINGW) Narrows to Key Level: A Tight Trading Range EmergesDemand Zone - dars.gov.et
Oncology Institute To Rally Over 64%? Here Are 10 Top Analyst Forecasts For Monday - Sahm
Cingulate director Hargroves buys $490,271 of common stock By Investing.com - Investing.com India
CING Q1 2026 Earnings: Wider-than-expected loss as pre-revenue biotech continues pipeline development - newsline.com
Finanzdaten der Cingulate Inc-Aktie (CING)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.64%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):